Edition:
India

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

104.41USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$104.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
536,597
52-wk High
$123.94
52-wk Low
$53.09

Latest Key Developments (Source: Significant Developments)

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company
Monday, 29 Jul 2019 

July 29 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY.EXACT SCIENCES CORP - TRANSACTION VALUED AT $2.8 BILLION.EXACT SCIENCES CORP - DEAL FOR $72.00 PER SHARE.EXACT SCIENCES CORP - UPON CLOSING, EXACT SCIENCES SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 91% OF COMBINED COMPANY.EXACT SCIENCES CORP - GENOMIC HEALTH STOCKHOLDERS WILL RECEIVE $27.50 IN CASH AND $44.50 IN SHARES OF EXACT SCIENCES STOCK.EXACT SCIENCES CORP - GENOMIC HEALTH STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 9% OF COMBINED COMPANY.EXACT SCIENCES CORP - COMBINED COMPANY POSITIONED TO DELIVER APPROXIMATELY $1.6 BILLION IN REVENUE AND APPROXIMATELY $1.2 BILLION IN GROSS PROFIT IN 2020.EXACT SCIENCES CORP - UPON CLOSING, EXACT SCIENCES SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 91% OF COMBINED COMPANY.  Full Article

Exact Sciences In Advanced Talks To Buy Genomic Health For About $2.8 Bln- Bloomberg
Saturday, 27 Jul 2019 

July 27 (Reuters) - :EXACT SCIENCES CORP IN ADVANCED TALKS TO BUY GENOMIC HEALTH INC FOR ABOUT $2.8 BILLION- BLOOMBERG.  Full Article

Exact Sciences Announces Offering Of $600 Million Convertible Senior Notes Due 2027
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $600 MILLION CONVERTIBLE SENIOR NOTES DUE 2027.  Full Article

Exact Sciences Reports Q4 Results
Friday, 22 Feb 2019 

Feb 21 (Reuters) - Exact Sciences Corp ::Q4 LOSS PER SHARE $0.44.SEES FY 2019 REVENUE $710 MILLION TO $730 MILLION.Q4 REVENUE $143 MILLION VERSUS REFINITIV IBES ESTIMATE OF $134.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $706.5 MILLION -- REFINITIV IBES DATA.  Full Article

Exact Sciences To Report $454 Mln - 455 Mln In Total Revenue, 71-Percent Growth For 2018
Monday, 7 Jan 2019 

Jan 6 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES TO REPORT $454-455M IN TOTAL REVENUE, 71-PERCENT GROWTH FOR 2018.SEES FY 2018 REVENUE $454 MILLION TO $455 MILLION.SEES Q4 2018 REVENUE $142.5 MILLION TO $143.5 MILLION.EXPECT APPROXIMATELY 94 PERCENT OF PATIENTS WHO COMPLETED A COLOGUARD TEST DURING Q4 TO HAVE NO OUT-OF-POCKET COSTS.  Full Article

Exact Sciences CEO Expects Revenue Of About $700 Million In 2019
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CEO SAYS PFIZER DEAL TO HAVE VERY LITTLE IMPACT ON COLOGUARD SALES IN 2018 - CONF CALL.EXACT SCIENCES EXPECTS REVENUE OF ABOUT $700 MILLION IN 2019 - CONF CALL.EXACT SCIENCES EXPECTS PFIZER DEAL TO HAVE IMPACT ON COLOGUARD SALES THROUGHOUT 2019 - CONF CALL.  Full Article

Exact Sciences Says Has Priced Public Offering Of 1 Pct Convertible Senior Notes Due 2025
Friday, 8 Jun 2018 

June 8 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES UPSIZING AND PRICING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES CORP - HAS PRICED ITS UNDERWRITTEN PUBLIC OFFERING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - OFFERING FROM $150 MILLION TO $190 MILLION AGGREGATE PRINCIPAL AMOUNT.EXACT SCIENCES CORP - INITIAL PUBLIC OFFERING PRICE FOR NOTES WILL BE 106.5% OF FACE VALUE PLUS ACCRUED INTEREST FROM JANUARY 17, 2018.EXACT SCIENCES CORP - NOTES WILL BE SENIOR, UNSECURED OBLIGATIONS OF COMPANY AND WILL BEAR INTEREST AT A RATE OF 1.0% PER ANNUM.  Full Article

Exact Sciences Announces Offering Of 1 Pct Convertible Senior Notes Due 2025
Friday, 8 Jun 2018 

June 7 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - NOTES ISSUANCE IS REOPENING OF, AND PART OF SAME SERIES AS, $690 MILLION AGGREGATE PRINCIPAL AMOUNT OF 1.0% SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025
Friday, 12 Jan 2018 

Jan 11 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION.  Full Article

Photo

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.